ClinicalTrials.gg
RecruitingNCT07589868HEAL FHA PilotUpdated Nov 6, 2026

Feasibility of a Digital Self-help Program for Functional Hypothalamic Amenorrhea (HEAL-FHA Pilot)

An interventional study of 10-week web-based psychoeducational program in Functional Hypothalamic Amenorrhea, sponsored by Karolinska Institutet. Recruiting at 2 sites in Sweden. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

How we know

Updated Nov 6, 2026Now RecruitingSite recruiting status changed+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

This study is a single-arm feasibility trial evaluating a 10-week web-based psychoeducational intervention for women with functional hypothalamic amenorrhea (FHA). The primary aim is to assess feasibility and acceptability prior to a future randomized controlled trial.

Read the detailed description

Intervention The intervention is delivered via a secure web-based platform over 10 weeks. Delivered via Inera's Stöd och behandling platform (1177) with BankID login; one module per week; no therapist support. It consists of sequentially released modules including psychoeducational content, reflective exercises, and practical strategies targeting factors relevant to FHA, including energy availability, stress regulation, recovery, nutrition, physical activity, and psychological well-being. The program is self-guided and designed for remote access. No therapist support is provided within the platform.

The intervention content has been developed through an iterative co-creation process involving clinicians (gynecology, psychology, physiotherapy, dietetics) and patient representatives.

Study procedures and setting Participants are recruited via clinical referral from gynecological outpatient services. All participants undergo baseline clinical assessment at the Gynecological Endocrinology Clinic at Karolinska University Hospital to confirm diagnosis of FHA prior to enrollment.

Assessments are conducted at baseline (T0), post-intervention at 10 weeks (T1), and follow-up at 4 and 8 weeks post-intervention (T2).

At baseline, diagnosis is confirmed through clinical evaluation, medical history, gynecological examination, and hormonal assessment consistent with hypogonadotropic hypogonadism. Psychiatric comorbidity is assessed using the DIAMOND Psychiatric Interview.

Self-report questionnaires are completed electronically via REDCap at T0, T1 and T2, assessing psychological and behavioral outcomes including perceived stress, coping, anxiety, depressive symptoms, eating-related behaviors, exercise patterns, and personality-related traits associated with FHA.

Outcomes Primary outcomes include feasibility and acceptability metrics: recruitment rate, retention, intervention completion, adherence to modules, and participant satisfaction.

Secondary outcome includes change in luteinizing hormone (LH) levels from baseline to post-intervention as a physiological marker of hypothalamic-pituitary-gonadal axis activity.

Exploratory outcomes include changes in psychological and behavioral measures from baseline to post-intervention and follow-up.

Statistical analysis Analyses are descriptive. Proportions are presented with exact 95% confidence intervals and changes from baseline with 95% confidence intervals; no formal hypothesis testing of effectiveness is planned. Missing data are described and not imputed.

Ethical considerations Participants not meeting eligibility criteria or requiring additional clinical care will be referred to appropriate healthcare services. The study is conducted in accordance with applicable ethical guidelines for human research.

02

Conditions studied

  • Functional Hypothalamic Amenorrhea

Browse trials for

Keywords

  • secondary amenorrhea
  • functional hypogonadotropic hypogonadism
  • relative energy deficiency
  • the female athlete triad
03

In context

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

This study's planned enrollment of 15 is below the median of 54 across 49 interventional studies indexed under Amenorrhea.

Browse Amenorrhea studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 6, 2026. See what changed

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Women aged 18-40 years with functional hypothalamic amenorrhea (hypogonadotropic hypogonadism) verified by a gynecologist; able to read and understand Swedish; access to an internet-enabled device and BankID; written .

Exclusion criteria

Exclusion Criteria:

Current anorexia nervosa, bulimia nervosa or binge-eating disorder according to the DIAMOND structured diagnostic interview (other specified feeding or eating disorder is not an exclusion criterion); severe psychiatric comorbidity requiring other or more intensive care, including psychosis; insufficient Swedish proficiency; other causes of amenorrhea, including pregnancy, thyroid disease, hyperprolactinemia and polycystic ovary syndrome.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Web-Based Psychoeducational Intervention

    Participants will complete a 10-week web-based psychoeducational intervention for functional hypothalamic amenorrhea, with assessments at baseline, post-treatment, and 4-week follow-up.

    Behavioral: 10-week web-based psychoeducational program

Interventions

  • Behavioral10-week web-based psychoeducational program

    The intervention is a 10-week, self-guided, web-based psychoeducational program targeting biopsychosocial mechanisms underlying functional hypothalamic amenorrhea, including stress, energy availability, and exercise-related behaviors. Content was developed by a multidisciplinary clinical team in collaboration with patient representatives.

06

What researchers measure

Primary outcomes

  1. Participant satisfaction

    1. Recruitment: number screened, eligible and enrolled, and proportion of eligible women who consent \[Time frame: October 2026-March 2027\]. 2. Retention: proportion of enrolled participants completing the 4-month assessment \[4 months\]. 3. Adherence: number of modules completed and proportion completing at least 5 of 10 modules (platform log data) \[10 weeks\]. 4. Treatment satisfaction: Client Satisfaction Questionnaire (CSQ-8) \[3 months\].

    Time frame: Post-treatment (10 weeks)

Secondary outcomes

  1. 1. Recruitment rate 2. Retention rate 3. Intervention completion rate 4. Perceived usefulness of intervention

    1. Proportion of eligible participants who consent to participate in the study. (Unit of Measure: percentage of eligible participants) 2. Proportion of participants completing post-treatment assessment at 10 weeks. (Unit of Measure: percentage of enrolled participants) 3. Proportion of participants completing all 10 modules of the web-based program. (Unit of Measure: percentage of enrolled participants) 4. Participant-rated perceived usefulness of the program assessed post-treatment using a standardized rating scale. (Unit of Measure: scale score) 5 . Treatment credibility \[3 weeks\]. 5. Negative effects: Negative Effects Questionnaire (NEQ-20) \[3 months\].

    Time frame: From enrollment to the end of study after 4 months

Other outcomes

  1. Psychiatric co-morbidity

    EDE-Q, PSS-14, GAD-7, PHQ-9, WHO-5, ISI, IPAQ and FSFI-6 \[baseline and 4 months\]; psychiatric diagnoses according to DIAMOND \[baseline\].

    Time frame: At enrollment and at study end

07

Study locations

2 of 2 sites recruiting
  • Women's Health Clinic, Karolinska University Hospital
    Stockholm, Stockholm County 17176, Sweden
    Recruiting
  • Karolinska University Hospital
    Stockholm, Sweden
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2026 (actual). Primary completion is estimated for Jul 2027, 8 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Jan 2026 → Nov 2026, primary completion Dec 2026 → Jul 2027 and completion Dec 2026 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2026
First posted
May 15, 2026
StartActual
Nov 2, 2026was Jan 2026
Primary completionEst.
Jul 31, 2027was Dec 2026
CompletionEst.
Jul 31, 2027was Dec 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 6, 2026
Sites
1 site added. Karolinska University Hospital is now Recruiting
Show site
  • Women's Health Clinic, Karolinska University Hospital · Stockholm, Sweden
Nov 6, 2026
Start date
Jan 1, 2026→Nov 2, 2026
Nov 6, 2026
Primary completion
Dec 31, 2026→Jul 31, 2027
Nov 6, 2026
Study completion
Dec 31, 2026→Jul 31, 2027
Nov 6, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedFemale participantsWomen aged 18-40 years Clinical diagnosis ofwith functional hypothalamic amenorrhea (hypogonadotropic hypogonadism) confirmedverified by clinical assessment Ability to understand and read Swedish Access to a computer and internet connection Willing andgynecologist; able to provideread and understand Swedish; access to an internet-enabled device and BankID; written informed consent.
Exclusion criteria
  • RemovedCurrent or past diagnosis of anorexia nervosa Severe psychiatric comorbidity (e.g., psychotic disorders) that may interfere with study participation Inability to understand or read Swedish Medical or gynecological conditions other than FHA that explain amenorrhea
  • AddedCurrent anorexia nervosa, bulimia nervosa or binge-eating disorder according to the DIAMOND structured diagnostic interview (other specified feeding or eating disorder is not an exclusion criterion); severe psychiatric comorbidity requiring other or more intensive care, including psychosis; insufficient Swedish proficiency; other causes of amenorrhea, including pregnancy, thyroid disease, hyperprolactinemia and polycystic ovary syndrome.
Nov 6, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionParticipant satisfaction: how it is measured was reworded
Nov 6, 2026
Secondary outcomes
1 time frame changed, 1 added, 1 description edited
What changed in the outcomes
  • Time frame1. Recruitment rate 2. Retention rate 3. Intervention completion rate 4. Perceived usefulness of interventionFrom enrollment to the end of treatment at 10 weeks → From enrollment to the end of study after 4 months
  • Description1. Recruitment rate 2. Retention rate 3. Intervention completion rate 4. Perceived usefulness of intervention: how it is measured was reworded
  • Addedother outcomePsychiatric co-morbidityTime frame: At enrollment and at study end
Nov 6, 2026
Contact
Study contact now listed: added h•••@ki.se · •••0000; added a•••@ki.se. See the current contact
Nov 6, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Karolinska University Hospital · Stockholm, SwedenContact added h•••@ki.se · •••0000Contact added a•••@ki.se · •••0000Contact added (no phone or email listed)
Nov 6, 2026
Title
A 10-Week Online Education Program for Women With Functional Hypothalamic Amenorrhea: Developing and Testing Feasibility and Acceptability→Feasibility of a Digital Self-help Program for Functional Hypothalamic Amenorrhea (HEAL-FHA Pilot)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Active, not recruiting→Recruiting
    1 site added. Karolinska University Hospital is now Recruiting
    Show site
    • Women's Health Clinic, Karolinska University Hospital · Stockholm, Sweden
    Start date Jan 1, 2026→Nov 2, 2026
    Primary completion Dec 31, 2026→Jul 31, 2027
    Study completion Dec 31, 2026→Jul 31, 2027
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedFemale participantsWomen aged 18-40 years Clinical diagnosis ofwith functional hypothalamic amenorrhea (hypogonadotropic hypogonadism) confirmedverified by clinical assessment Ability to understand and read Swedish Access to a computer and internet connection Willing andgynecologist; able to provideread and understand Swedish; access to an internet-enabled device and BankID; written informed consent.
    Exclusion criteria
    • RemovedCurrent or past diagnosis of anorexia nervosa Severe psychiatric comorbidity (e.g., psychotic disorders) that may interfere with study participation Inability to understand or read Swedish Medical or gynecological conditions other than FHA that explain amenorrhea
    • AddedCurrent anorexia nervosa, bulimia nervosa or binge-eating disorder according to the DIAMOND structured diagnostic interview (other specified feeding or eating disorder is not an exclusion criterion); severe psychiatric comorbidity requiring other or more intensive care, including psychosis; insufficient Swedish proficiency; other causes of amenorrhea, including pregnancy, thyroid disease, hyperprolactinemia and polycystic ovary syndrome.
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionParticipant satisfaction: how it is measured was reworded
    Secondary outcomes 1 time frame changed, 1 added, 1 description edited
    What changed in the outcomes
    • Time frame1. Recruitment rate 2. Retention rate 3. Intervention completion rate 4. Perceived usefulness of interventionFrom enrollment to the end of treatment at 10 weeks → From enrollment to the end of study after 4 months
    • Description1. Recruitment rate 2. Retention rate 3. Intervention completion rate 4. Perceived usefulness of intervention: how it is measured was reworded
    • Addedother outcomePsychiatric co-morbidityTime frame: At enrollment and at study end
    Contact Study contact now listed: added h•••@ki.se · •••0000; added a•••@ki.se. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Karolinska University Hospital · Stockholm, SwedenContact added h•••@ki.se · •••0000Contact added a•••@ki.se · •••0000Contact added (no phone or email listed)
    Title A 10-Week Online Education Program for Women With Functional Hypothalamic Amenorrhea: Developing and Testing Feasibility and Acceptability→Feasibility of a Digital Self-help Program for Functional Hypothalamic Amenorrhea (HEAL-FHA Pilot)
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07589868
Collaborators
Karolinska University Hospital, FoU Centrum, Landstinget Sörmland
Responsible party
Hedvig Engberg (MD PhD, Karolinska Institutet) — Principal investigator
First posted
May 15, 2026
Start date
Nov 2, 2026
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Hedvig Engberg, MD, Associate Professor
Contact
hedvig.engberg@ki.se
+46 08 123 700 00
Anna Strandqvist, PhD, clinical psychologist
Contact
anna.strandqvist@ki.se

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion